IMMUNOVANT INC

Immunovant (IMVT) reports Q1 2026 results: $797.8 M cash, $14 M R&D spend, and on‑track data for IMVT‑1402 across six indications, including Graves’ disease and myasthenia gravis.

Immunovant’s batoclimab fails Phase‑3 thyroid eye disease trial, slashing stock and spotlighting the high risk of FcRn‑blocking immunotherapies.

Immunovant Inc. has announced promising results for its Graves’ disease treatment, achieving durable and treatment-free six-month remission in patients, marking a potential breakthrough in the treatment of this chronic autoimmune disorder.